STRS Ohio’s Novo Nordisk NVO Stock Holding History

STRS Ohio’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,208	Closed	-$289K	–	2206
2022 Q1	$289K	Sell	5,208 -10,792	-67%	-$554K	﹤0.01%	1611
2021 Q4	$896K	Hold	16,000	–	–	﹤0.01%	1185
2021 Q3	$768K	Buy	+16,000	New	+$774K	﹤0.01%	1294

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

STRS Ohio's NVO Position: Q2 2022 in Review

STRS Ohio sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 5,208 shares — an estimated $289K sold.

STRS Ohio first reported a position in NVO in Q3 2021 and held it in 3 quarters. The position peaked at $896K in Q4 2021. 933 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

STRS Ohio reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 5,208 Novo Nordisk shares in Q2 2022, an estimated $289K.
STRS Ohio first reported a position in Novo Nordisk in Q3 2021 and held it in 3 quarters.
STRS Ohio's Novo Nordisk position peaked at $896K in Q4 2021.
933 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.